These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

752 related articles for article (PubMed ID: 30287548)

  • 1. Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment.
    Teh JLF; Aplin AE
    Clin Cancer Res; 2019 Feb; 25(3):921-927. PubMed ID: 30287548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
    Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
    Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.
    Parylo S; Vennepureddy A; Dhar V; Patibandla P; Sokoloff A
    J Oncol Pharm Pract; 2019 Jan; 25(1):110-129. PubMed ID: 29726787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors.
    Patel HK; Tao N; Lee KM; Huerta M; Arlt H; Mullarkey T; Troy S; Arteaga CL; Bihani T
    Breast Cancer Res; 2019 Dec; 21(1):146. PubMed ID: 31852484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.
    Braal CL; Jongbloed EM; Wilting SM; Mathijssen RHJ; Koolen SLW; Jager A
    Drugs; 2021 Feb; 81(3):317-331. PubMed ID: 33369721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDK4/6 blockade in breast cancer: current experience and future perspectives.
    Zardavas D; Pondé N; Tryfonidis K
    Expert Opin Investig Drugs; 2017 Dec; 26(12):1357-1372. PubMed ID: 29027483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CDK4/6 inhibitors for the treatment of advanced hormone receptor positive breast cancer and beyond: 2016 update.
    O'Sullivan CC
    Expert Opin Pharmacother; 2016 Aug; 17(12):1657-67. PubMed ID: 27322766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
    Bonelli M; La Monica S; Fumarola C; Alfieri R
    Biochem Pharmacol; 2019 Dec; 170():113676. PubMed ID: 31647925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.
    Piezzo M; Cocco S; Caputo R; Cianniello D; Gioia GD; Lauro VD; Fusco G; Martinelli C; Nuzzo F; Pensabene M; De Laurentiis M
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting CDK4/6 in patients with cancer.
    Hamilton E; Infante JR
    Cancer Treat Rev; 2016 Apr; 45():129-38. PubMed ID: 27017286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
    Formisano L; Lu Y; Servetto A; Hanker AB; Jansen VM; Bauer JA; Sudhan DR; Guerrero-Zotano AL; Croessmann S; Guo Y; Ericsson PG; Lee KM; Nixon MJ; Schwarz LJ; Sanders ME; Dugger TC; Cruz MR; Behdad A; Cristofanilli M; Bardia A; O'Shaughnessy J; Nagy RJ; Lanman RB; Solovieff N; He W; Miller M; Su F; Shyr Y; Mayer IA; Balko JM; Arteaga CL
    Nat Commun; 2019 Mar; 10(1):1373. PubMed ID: 30914635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.
    Poratti M; Marzaro G
    Eur J Med Chem; 2019 Jun; 172():143-153. PubMed ID: 30978559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting CDK4/6 pathways and beyond in breast cancer.
    Ribnikar D; Volovat SR; Cardoso F
    Breast; 2019 Feb; 43():8-17. PubMed ID: 30359883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HR+, HER2- Advanced Breast Cancer and CDK4/6 Inhibitors: Mode of Action, Clinical Activity, and Safety Profiles.
    Sammons SL; Topping DL; Blackwell KL
    Curr Cancer Drug Targets; 2017; 17(7):637-649. PubMed ID: 28359238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.
    Scott SC; Lee SS; Abraham J
    Semin Oncol; 2017 Dec; 44(6):385-394. PubMed ID: 29935900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
    Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
    Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.